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Homeodomain-containing proteins are transcription fac-
tors regulating the coordinated expression of multiple
target genes involved in development, dierentiation and
cellular transformation. In this study, we demonstrated
that HOXB7, one member of this family, behaved as a
transactivator in breast cancer cells. Deletion of either
the HOXB7 N-terminal domain or the C-terminal acidic
tail abolished this transcriptional eect, suggesting a
combination of distinct functional transactivating do-
mains. HOXB7 physically interacted both in vitro and in
vivo with the coactivator CREB-binding protein (CBP).
This interaction led to an enhanced transactivating
potential and required the N-terminal of HOXB7 as
well as two domains located at the C-terminal part of
CBP. Moreover, trichostatin A, a deacetylase inhibitor,
strongly enhanced the transcriptional properties of
HOXB7. Our data therefore indicate that HOX proteins
can directly interact with CBP and that acetylation/
deacetylation may regulate their transcriptional proper-
ties.
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Introduction
Genetic programs governing development, differentia-
tion and cell growth imply the regulated transcription
of a variety of genes through the action of multiple
proteins defined as ‘general transcription factors’
(GTFs), ‘activators’, ‘repressors’ and ‘mediators’ or
‘cofactors’, depending on their exact function (Sauer
and Tjian, 1997).
The CBP (CREB-binding protein)/p300 proteins are
coactivators which interact with the phosphorylated
form of CREB (cAMP response element binding)
(Chrivia et al., 1993) and with a number of other
transcription factors including c-jun, c-fos, nuclear
receptors, c-Myb. MyoD, YY1, Sap-1a, sterol regula-
tory element binding protein (SREBP), E2F1/DP1 (see
Shikama et al. (1996) for a review), NF-kB p65 (Rel A)
(Perkins et al., 1997), p53 (Avantaggiati et al., 1997;
Gu and Roeder, 1997a; Lill et al., 1997) and Smad
proteins (Feng et al., 1998; Janknecht et al., 1998). All
these interactions suggest that CBP acts as a bridge or
an ‘adaptator’ between the activators or repressors and
the initiation complex containing the GTFs and the
RNA polymerase II (Eckner et al., 1994; Arany et al.,
1995). CBP also interacts with other coactivators such
as RAC3 (Li and Don Chen, 1998) and steroid
receptor coactivator-1 (SRC-1) (Hanstein et al., 1996;
Smith et al., 1996) and has been copurified with the
holoenzyme complex along with BRCA1 (Neish et al.,
1998). CBP is now considered as an ‘integrator’ (Kamei
et al., 1996) or ‘co-integrator’ (Chakravarti et al., 1996)
of a variety of signaling pathways. Although both CBP
and p300 proteins share similar functional properties in
transient transfection experiments, they have distinct
functions during retinoic-acid-induced dierentiation
(Kawasaki et al., 1998).
An histone acetyltransferase activity has been
attributed to the CBP/p300 proteins (Bannister and
Kouzarides, 1996; Ogryzko et al., 1996). In other
words, CBP can enhance removal of positive charges
by acetylation of lysine residues at the N-terminal tail
of histones, which presumably destabilizes the nucleo-
some and facilitates the access of transcription factors
to DNA. This histone acetyltransferase activity is
required for in vivo transcription regulation (Marti-
nez-Balbas et al., 1998). CBP also recruits P/CAF, a
protein harboring a histone acetyltransferase activity as
well (Yang et al., 1996). Moreover, CBP/p300 can also
acetylate TFIIE, TFIIH (Imhof et al., 1997), the
erythroid Kruppel-like factor (Zhang and Bieker,
1998), p53 and activate p53 biochemical function (Gu
and Roeder, 1997b).
Homeodomain-containing proteins have been identi-
fied as transcriptional regulators controlling the
expression of genes involved in development, differ-
entiation and tumoral transformation (Levine and
Hoey, 1988; Favier and Dolle´ 1997; Mark et al.,
1997; Shimamoto et al., 1998). They share a highly
conserved 60 amino acid DNA-binding domain (the
‘homeodomain’) (Gehring et al., 1994). Although each
member of this family exhibits in vivo specificity as
demonstrated by targeted gene knock-out experiments,
they share very similar DNA-binding anities in vitro,
suggesting that protein – protein interactions mediate
their specificity. For instance, the homeodomain-
containing extradenticle (exd)/Pbx gene products have
been identified as cofactors of HOX gene products
(Mann and Chan, 1996). These interactions require the
pentapeptide, a conserved domain located upstream
from the DNA-binding domain of most HOX proteins
(Chang et al., 1995) as well as the Hox cooperativity
motif (‘HCM’), a sequence carboxy terminal to the Pbx
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homeodomain (Chang et al., 1997). Since AbdB-like
HOX proteins do not harbor the pentapeptide, most of
these products cannot interact with Pbx (Shen et al.,
1997), thus raising the possibility that other partners
might be required. Indeed, a recent report demon-
strated the formation of heterodimeric complexes
between Hox and Meisl proteins (Shen et al., 1997).
It is likely that other proteins yet to be identified are
involved in such processes.
HOXB7 was initially isolated from an SV40-
transformed human fibroblast cDNA library (Si-
meone et al., 1987) and proposed to be involved in a
variety of developmental processes. The HOXB7
protein has also been implicated in hematopoietic
dierentiation as well as in lymphoid development
(Shen et al., 1989; Deguchi et al., 1991; Lill et al., 1995;
Magli, 1998). The HOXB7 protein can bind DNA
(Corsetti et al., 1992) and activate transcription from
distinct promoters in a variety of cell lines (Care et al.,
1996; Chariot et al., 1998; Sanlioglu et al., 1998).
However, the functional domains that mediate HOXB7
transcriptional properties as well as its interacting
partners remain to be identified.
In this report, we demonstrated that both the N-
terminal domain and the C-terminal acidic tail of
HOXB7 are required for transactivation. Moreover, we
illustrated the physical interaction between HOXB7
and the coactivator CBP in vitro and in vivo. We also
showed that deacetylase inhibition by trichostatin A
(TSA), potentiates the HOXB7 transactivating eect.
Results
A combinatorial code mediates the HOXB7
transactivation eect
We previously demonstrated that the HOXB7 protein
can activate transcription in MDA-MB231 cells
(Chariot et al., 1998). Indeed, cotransfection of the
pTCBS plasmid and the HOXB7 expression vector
increased the luciferase activity 3.5- to 3.7-fold over
basal activity in a dose-dependent manner (Figure 1b,
left panel). A decrease in the transactivating eect was
observed when 2 mg of HOXB7-expression vector was
transfected, probably reflecting a squelching eect
(Figure 1b, left panel). The commitment of the
HOXB7 binding to the CBS sequence was indirectly
confirmed by cotransfection of the pT109 reporter
plasmid.
To further map the domain(s) that mediate(s)
HOXB7 transcriptional activity, expression vectors
generating HOXB7 proteins deleted either in the N-
or in the C-terminal domain were constructed (Figure
1a). ‘B7-DN18’, ‘DN54’ and ‘DN86’ generated HOXB7
gene products lacking 18, 54 and 86 amino acids in the
N-terminal region, respectively. These proteins har-
bored the pentapeptide domain, whereas the ‘B7-
DN129’ construct encoded a HOXB7 gene product
lacking the pentapeptide. The product ‘B7-DC12’
lacked 12 amino acid in the C-terminal region and
did not contain the acidic tail, whereas the constructs
‘B7-DC34’. ‘B7-DC80’ and ‘B7-DC97’ were deleted of
34, 80 and 97 amino acids, respectively. Neither ‘B7-
DC80’ nor ‘B7-DC97’ products contained the home-
odomain. In transient expression experiments, the ‘B7-
DN18’ product transactivated (a 2.3- to 2.8-fold
induction of luciferase activity) (Figure 1b, middle
panel) almost as eciently as the wild-type HOXB7
protein. A further deletion of 54, 86 or 129 amino acids
progressively decreased the transactivating ability of
the HOXB7 protein, suggesting that the N-terminal
domain of this gene product mediates its transactivat-
ing eect. Interestingly, the ‘B7-DC12’ product did not
exhibit any transactivation activity and a dose-
dependent repressing eect was even observed (Figure
1b, right panel), indicating that the C-terminal acidic
Figure 1 (a) Schematic representation of the HOXB7 expression
vectors. These vectors generate products deleted either in their N-
terminal domain (‘B7-DN18’, ‘DN54’, ‘DN86’ and ‘B7-DN129’) or
in their C-terminal domain (‘B7-DC12’, B7-DC34’, ‘B7-DC80’ and
‘B7-DC97’). The homeodomain is illuatrated by a hatched
rectangle while both the pentapeptide and the acidic C-terminal
tail are also shown. The expected molecular mass of the resulting
proteins is given on the right. (b) Analysis of the transcriptional
properties of HOXB7 wild-type (left panel) and HOXB7 mutant
gene products deleted either in their N-terminal domain (middle
panel) or in their C-terminal domain (right panel). The pT109
does not contain any HOX-binding sequence and was used as a
negative control. Cells were transfected with increasing amounts
of HOXB7 wild-type or mutant expression vectors (0.5, 1 or 2 mg)
together with 1 mg of reporter plasmid. The figure shows the
relative luciferase activity over the activity observed with 1 mg of
the pTCBS or pT109 reporter plasmids alone. Each value
represents the mean (+s.d.) of at least three independent
experiments after normalization to the protein concentration of
the extracts
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tail is also involved in the HOXB7-dependent
transactivation eect. Therefore, we conclude that
both the N-terminal domain and the acidic C-terminal
tail are required for the HOXB7 transcriptional
properties.
The HOXB7 protein physically interacts with the
coactivator CBP in vitro
We investigated whether HOXB7 could interact with
the coactivator CBP, which is a large and complex
protein harboring distinct functional domains (Figure
2a). The GST-CBP fusion proteins (Figure 2b) were
expressed in E.coli, purified and incubated with in
vitro-translated HOXB7 protein. HOXB7 was not
precipitated by the GST-CBP ‘1’ (Figure 3a, lane 1),
a fusion protein harboring both the receptor-interact-
ing domain (‘RID’) and the CREB binding domain
(‘KIX’) of CBP nor by GST-CBP ‘2’ (Figure 3a, lane
2) which harbors the CREB binding domain (‘KIX’),
suggesting that there was no physical interaction
between HOXB7 and these parts of the CBP protein.
However, when HOXB7 was incubated with the GST-
CBP ‘3’ fusion protein, a weak signal was detected
(Figure 3a, lane 3), suggesting that the histone
acetyltransferase domain contributes to the interaction
with HOXB7 in vitro. Moreover, HOXB7 was clearly
precipitated by the GST-CBP ‘4’ fusion protein (Figure
3a. lane 4), suggesting that the cystein-histidine-rich ‘C/
H3’ domain of CBP physically interacts with HOXB7.
A signal was also observed when the GST-CBP ‘5’
fusion protein which harbors the C-terminal domain of
CBP was incubated with the homeodomain-containing
protein (Figure 3a, lane 5). These results suggest that
HOXB7 interacts in vitro with two domains of CBP
known to mediate physical interaction with other
transcription factors such as c-fos, TFIIB and MyoD
for the C/H3 sequence and p53 for the C-terminal
domain (Figure 2a).
HOXB7 N-terminal domain is required for interaction
with CBP
To further map the HOXB7 domain(s) involved in the
physical interaction with CBP. various HOXB7 vectors
were used as templates for in vitro translation, and
translated products were incubated with the GST-CBP
‘4’ fusion protein. As illustrated in Figure 3b, the
deletion of the first 18 amino acids clearly abolished
HOXB7-CBP interaction (lane 5). Moreover, we could
not detect any interaction between CBP and ‘B7-
DN54’, ‘B7-DN86’ and ‘B7-DN129’ (Figure 3b, lanes 8,
11 and 14). The N-terminal domain of HOXB7 is thus
required for the interaction with CBP in vitro.
To determine whether other HOXB7 domains were
involved in the interaction with CBP, several HOXB7
vectors deleted in the C-terminal domain were in vitro
translated. As illustrated in Figure 3c, the mutant B7,
which codes for a naturally occurring truncated
HOXB7 protein lacking two amino acids within the
acidic tail (Chariot et al., 1998) and the ‘B7-DC12’
protein interacted with CBP, just as eciently as the
wild-type HOXB7 gene product (lanes 5 and 8). The
‘B7-DC34’, ‘B7-DC80’ and ‘B7-DC97’ proteins which
Figure 2 (a) Schematic representation of the CBP coactivator. All the proteins known to physically interact with CBP are
mentioned next to their respective interacting CBP domains. ‘AR’: androgen receptor; ‘cdk-2’: cyclin-dependent kinase-2; ‘C/H3’:
cystein-histidine-rich domain 3; ‘ER’: estrogen receptor; ‘GR’: glucocorticoid receptor; ‘HAT’: histone acetyltransferase; ‘PR’:
progesterone receptor; ‘RID’: receptor interacting domain; ‘RXR’: retinoid X receptor; ‘TBP’: TATA-binding protein; ‘TR’: thyroid
receptor. (b) Schematic representation of the various GST-CBP fusion proteins used in this study
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lack the acidic tail and a part or the entirety of the
homeodomain could still interact with CBP in vitro
(Figure 3c, lane 11, 14 and 17). The in vitro interaction
between HOXB7 and CBP thus requires the N-
terminal of this HOX protein.
CBP enhances the transactivation potential of HOXB7
in MDA-MB231 cells
To determine whether HOXB7 and CBP interacted in
vivo, we performed transient expression experiments in
MDA-MB231 cells using either pTCBS or pT109
reporter plasmids, the CMX-CBP expression vector,
and HOXB7 expression vectors (Figure 1a). CBP
enhanced the HOXB7-mediated transactivation, since
a 160-fold induction of luciferase activity was measured
when both HOXB7-expression vector and a CMX-CBP
expression vector were cotransfected with the pTCBS
plasmid (Figure 4a). The luciferase activity observed
with the pT109 reporter plasmid was much weaker
(Figure 4a), demonstrating that the eect is mainly
mediated by the binding of HOXB7 to the CBS. We
also constructed a CBP mutant named ‘CBPDC’ that
lacks the HAT, C/H3 and C-terminal domains (Figure
4a). The induction of luciferase activity was much less
intense when we cotransfected this CBP mutant with
the HOXB7-expression construct and the pTCBS
plasmid, thus confirming that these CBP domains are
required for the interaction with HOXB7 in vivo as well
as in vitro. Cotransfection of both the ‘B7-DN129’ and
CBP expression vectors with the pTCBS reporter
plasmid did not significantly enhance the eect of this
deleted HOXB7 product (Figure 4b), confirming that
the N-terminal domain of HOXB7 is necessary for
interaction with the coactivator as shown in vitro.
Modulation of HOXB7 transcriptional properties by
protein acetylation/deacetylation was investigated by
treating MDA-MB231 cells for 20 h with TSA, a
deacetylase inhibitor. TSA strongly induced luciferase
activity after transfection of both pTCBS and HOXB7
expression vectors (Figure 4c). Interestingly, TSA did
not significantly induce the transactivation eect of
either the ‘B7-DN129’ product or the ‘B7-DN18’
protein, which still exhibited transactivation abilities
(Figure 4c). Taken together, our results suggest that
HOXB7 transcriptional properties might be regulated
by acetylation/deacetylation through the N-terminal
domain of this transcription factor.
We further investigated in vivo interaction between
CBP and HOXB7 proteins by performing Mamma-
lian two-hybrid system experiments in MDA-MB231
cells using both GAL4-CBP and HOXB7-VP16
expression vectors and the pSG5 reporter plasmid
that harbors a GAL4 binding sequence upstream
from a minimal E1B promoter and a CAT gene. No
significant induction of the CAT activity was
measured when the HOXB7-VP16 expression vector
was cotransfected with the GAL4 expressing con-
struct and the reporter plasmid, whereas a 2.8-fold
induction was observed when both GAL4-CBP and
VP16 were expressed, probably because of the
intrinsic transactivation ability of the wild-type CBP
protein (Figure 5). A sixfold induction of CAT
activity was measured when both GAL4-CBP and
HOXB7-VP16 expressing constructs were expressed
(Figure 5). Moreover, when the HOXB7-VP16 was
cotransfected with the ‘GAL4-mCBP’ construct that
generates a GAL4-CBP fusion protein deleted of
both the C/H3 and Q-rich domains of CBP, the
induction of CAT activity was significantly reduced.
These results confirmed that HOXB7 and CBP
proteins interact in vivo through the C/H3 and Q-
rich domain of the coactivator.
Discussion
In this paper, we have demonstrated that the
transactivating eect of HOXB7 in MDA-MB231
cells requires both the N-terminal domain and the C-
terminal acidic sequence, thus suggesting a ‘combina-
torial code’ that mediates HOXB7 transcriptional
properties. This ‘combinatorial code’ hypothesis is
supported by other studies demonstrating that the
transcriptional properties of other HOX proteins are
also mediated by a unique combination of several
Figure 3 In vitro protein–protein interaction between HOXB7
and CBP. (a) The in vitro translated wild-type HOXB7 gene
product (‘B7’) was incubated with the GST-CBP‘1’ (lane 1), GST-
CBP‘2’ (lane 2), GST-CBP‘3’ (lane 3), GST-CBP‘4’ (lane 4), GST-
CBP‘5’ (lane 5) or with the GST protein used as a negative
control (lane 6). Lane ‘B7’ represents the in vitro translated
HOXB7 protein. (b) and (c): Incubation of the GST-CBP‘4’ (lanes
2, 5, 8, 11, 14, 17) or the GST protein (lanes 3, 6, 9, 12, 15, 18)
with various in vitro translated HOXB7 proteins deleted either in
their N-terminal (b) or in the C-terminal domain (c). In each case,
10% of in vitro translated material was run as control (lanes 1, 4,
7, 10, 13, 16)
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domains (Schnabel and Abate-Shen, 1996; Zhang et al.,
1996; Vigano et al., 1998).
Despite of the in vivo biological specificity of each
HOX gene product, all these transcription factors share
very similar in vitro DNA-binding anities. Protein –
protein interactions thus likely play a major role in the
regulation of their function. Partners for HOX proteins
are, for instance, Pbx and Meis proteins (Mann and
Chan, 1996; Shen et al., 1997). Since most of these
proteins have yet to be identified, we investigated
whether the coactivator CBP could modulate the
transcriptional properties of HOXB7. Mammalian
two-hybrid system experiments, transient transfections
and in vitro studies indicated that HOXB7 and CBP
interact in vitro and in vivo. Interaction between
HOXB7 and CBP requires the HOXB7 N-terminal
domain, which is also involved in interactions with
other transcription factors such as Meis 1 (Shen et al.,
Figure 5 Interaction between the HOXB7 and CBP proteins by Mammalian two-hybrid system. The pG5 reporter plasmid is
schematically represented. All the expression vectors that generate the fusion proteins are illustrated. The MDA-MB231 cells were
transfected with 1 mg of the pG5 and 2 mg of expression vectors. The figure shows the relative CAT activity over the activity
measured with 1 mg of the pG5 reporter plasmid alone. Each value represents the mean (+s.d.) of at least three independent
experiments after normalization
Figure 4 CBP and a histone deacetylase inhibitor increase HOXB7 transcriptional activity. MDA-MB231 cells were transfected
with HOXB7 and/or CBP expression vectors together with the pTCBS (hatched columns) or pT109 (white columns) reporter
plasmids. Cellular extracts were prepared and luciferase activities determined. (a) Cotransfection with the HOXB7 expression vector
(1 mg) together with expression vectors coding for wild-type (CBP) or mutant (CBPDC) protein (2 mg). (b) Cotransfection of the ‘B7-
DN129’ expression vector (1 mg) together with increasing amounts of the CBP expression vector (0.5, 1 or 2 mg). (c) After
transfection with the HOXB7 expression vector (1 mg), the ‘B7-DN129; or the ‘B7-DN18’ expression vectors (1 mg), MDA-MB231
cells were left untreated (–) or treated for 20 h with TSA (400 nM) as indicated in the figure
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1997). Since this N-terminal domain is less conserved
between the various homeodomain-containing proteins,
it is tempting to postulate that interaction with CBP
contributes to the in vivo specificity of HOXB7.
However, it is likely that CBP mediates the transcrip-
tional eect of other homeodomain-containing pro-
teins. In this context, a recent study has demonstrated
that the pituitary-specific factor Pit-1 requires a co-
activator complex that includes both CBP and p/CAF
(Xu et al., 1998).
TSA enhanced the transactivating eect of the wild-
type HOXB7 protein in MDA-MB 231 cells. This
deacetylase inhibitor has been previously described as
an activator of the gamma globin gene (McCarey et al.,
1997) and the WAF1/Cip1 gene promoter through Sp1
sites (Sowa et al., 1997). Moreover, TSA can potentiate
retinoid receptor action by altering the chromatin
structure within the RARb2 promoter (Minucci et al.,
1997). In vivo modification of the chromatin conforma-
tion at the HOX-binding sites may then facilitate the
access of the homeodomain-containing proteins to
regulating sequences. Moreover, our results raise the
possibility that HOXB7 function may be regulated by its
acetylation, a phenomenon already described for p53
(Gu and Roeder, 1997b), TFIIE, TFIIH (Imhof et al.,
1997) and the erythroid Kruppel-like factor (Zhang and
Bieker, 1998). The acetylation would occur in the N-
terminal domain of HOXB7, since we demonstrated that
TSA does not significantly enhance the transactivation
eect of two HOXB7 gene products which lack this
region. Moreover, deletion of the CBP HAT domain
almost completely abolished CBP functional interaction
with HOXB7. Alternatively, the acetylation of a cofactor
could be required for HOXB7 optimal transcriptional
activity. Taken together, these observations suggest that
the very strong transcriptional eect observed when
HOXB7 and CBP were expressed simultaneously could
be due to direct interaction between CBP and HOXB7
that would bridge HOXB7 with the transcription
machinery and/or to a reaction of acetylation targeting
either HOXB7 itself or a cofactor interacting with
HOXB7 N-terminal domain.
The Rubinstein-Taybi syndrome (‘RTS’) is an
autosomal dominant syndrome associated with point
mutations in the CBP gene (Petrij et al., 1995) and is
characterized by craniofacial malformations, broad
thumbs, broad big toes and mental retardation. The
mutations within the CBP gene lead to the expression
of truncated proteins unable to interact with CREB.
This hypothesis is supported by a recent study
demonstrating a partial similarity to the ‘RTS’
syndrome in embryos lacking a single Cbp allele
(Tanaka et al., 1997). On the other hand, targeted
gene knock-out experiments aecting one or two HOX
genes clearly cause developmental malformations
(Mark et al., 1997). Our data suggest that part of the
RTS phenotype might be related to a loss of HOX
protein activities during development. Further studies
are certainly required to investigate whether a CBP-
HOX protein complex is functional during embryogen-
esis. Moreover, alterations of the CBP/p300 human
gene sequences also lead to hematological malignancies
(see Giles et al., 1998 for a review) whereas a variety of
oncogenic translocations involves HOX genes (see
Shimamoto et al., 1998 for a recent review). Taken
together, these observations suggest that both CBP and
HOX proteins levels of expression are critical for
cellular dierentiation and that CBP alteration may
contribute to multiple diseases.
Materials and methods
Cell line and treatment
The MDA-MB231 cell line was obtained from the American
Type Tissue Culture Collection (Rockville, MD, USA) and
maintained in RPMI medium. MDA-MB231 cells were
treated with TSA 400 nM (Sigma, Bornem, Belgium) for
20 h before lysis.
Expression plasmids
Coding sequences of the HOXB7 gene and of a naturally
occuring mutated allele lacking two amino acids in its C-
terminal sequence (Chariot et al., 1998) were subcloned by
polymerase chain reaction (PCR) into the expression vector
pcDNA3 (Invitrogen. San Diego, CA, USA). Expression
vectors generating truncated HOXB7 gene products were
constructed by PCR (Figure 1a). The constructs ‘B7-DN18’,
‘DN54’, ‘DN86’ and ‘DN129’ generate HOXB7 gene products
lacking the 18, 54, 86 and 129 N-terminus amino acids,
respectively. The constructs ‘B7-DC12’, ‘B7-DC34’, ‘B7-DC80’
and ‘B7-DC97’ encode HOXB7 proteins lacking the 12, 34, 80
and 97 C-terminal amino acids, respectively. The pT109 and
pTCBS reporter plasmids were provided by Dr Zappavigna
(Laboratory of Gene Expression, Department of Biology and
Technology, Istituto Scientifico H.S. Raaele, Milan, Italy).
The pTCBS plasmid contains an eightfold multimerized form
of a homeodomain consensus binding sequence (CBS) cloned
upstream from a HSV-TK promoter and of a luciferase
(LUC) reporter gene whereas the pT109 construct does not
contain the CBS sequence and is used as a negative control
(Zappavigna, 1994).
The CMX-CBP expression vector was kindly provided by
Dr Evans (The Gene Expression Laboratory, The Salk Institute
for Biological Studies, La Jolla, CA, USA). A functional mouse
full-length CBP protein is generated from this vector (Chrivia et
al., 1993). A CBP mutant named ‘CBPDC’ that lacks the HAT,
the C/H3 and the C-terminal domains was amplified by PCR
and subcloned in the pcDNA3 vector.
In vitro translation
In vitro translations were performed using the ‘Wheat germ
TNT’ kit (Promega, Madison, WI, USA) with 1 mg of DNA
template, 1 ml of T7 polymerase and [35S] methionine. Two ml
of the reaction products were separated by electrophoresis on
a 12% polyacrylamide gel followed by autoradiography.
In vitro protein – protein interactions
Plasmids containing fusion genes of GST-CBP ‘1’ (aa 1 – 1099
of CBP), GST-CBP ‘3’ (aa 1099 – 1620) and GST-CBP ‘4’ (aa
1620 – 1877) constructs (Bannister and Kouzarides, 1996)
were kindly provided by Dr Kouzarides (Wellcome/CRC
Institute, Cambridge, UK) whereas the GST-CBP ‘2’ (aa
390 – 790) and GST-CBP ‘5’ (aa 1990 – 2441) plasmids (Gu
and Roeder, 1997a) were kindly provided by Dr Roeder
(Laboratory of Biochemistry and Molecular Biology, The
Rockfeller University, New York, NY, USA).
Expression and purification of GST fusion proteins were
performed as described (Kaelin et al., 1991) with modifica-
tions in the composition of the NENT buer (NaCl 250 mM,
EDTA 1 mM, Tris 20 mM pH 8, NP-40 1.5%). Protein –
protein interactions were studied by incubating an aliquot of
GST-CBP fusion protein bound to glutathione-Sepharose
beads with 10 ml of in vitro translated protein in 200 ml of
TWB buer (HEPES 20 mM pH 7.9, NaCl 60 mM, dithio-
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threitol 1 mM, MgCl2 6 mM, 8.2% glycerin, EDTA 0.1 mM)
for 1 h at 48C. After six washes of the beads in NENTM
buer, the precipitates were run on an SDS-polyacrylamide
gel before autoradiography.
Transient transfections and luciferase assays
Transfections in MDA-MB 231 cells were performed using
1 mg of reporter plasmid and up to 2 mg of distinct expression
vectors per 35-mm dish as described (Chariot et al., 1998).
Cells were harvested 48 h after transfection and luciferase
assays were performed as described (Chariot et al., 1998).
Transfection eciency was assessed by transfection of a
Luciferase reporter gene driven by the cytomegalovirus
(CMV) promoter and by measuring the induction of the
LUC activity after cotransfection of the pTCBS reporter
plasmid with the HOXB7 expression vector. Luciferase
activities were normalized to the protein concentration of
the extracts.
Mammalian two-hybrid system
The coding sequence of the HOXB7 gene was subcloned in
frame with the activation domain of VP16, whereas a GAL4-
CBP expressing construct generating a fusion product
containing the coding sequence of CBP in frame with the
DNA-binding domain of GAL4 was kindly provided by Dr
Evans. A GAL4-CBP construct harboring a stop mutation at
amino acid 1630 of the CBP coding sequence and named
‘GAL4-mCBP’ was kindly provided by Dr Montminy
(Laboratory of Advanced Genetic Techniques, Harvard
Medical School, Cambridge, MA, USA). Transfection of
DNA in MDA-MB 231 cells was performed as described
(Chariot et al., 1998) and included up to 2 mg of expressing
vectors with 1 mg of a pG5 reporter plasmid harboring five
GAL4 binding sequences upstream from a minimal E1B
promoter and a CAT gene (Clontech, Palo Alto, CA, USA).
Total amounts of DNA were kept constant by adding
appropriate amounts of pcDNA3. Cells were harvested 48 h
after transfection and CAT assays were performed as
described (Neumann et al., 1987).
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